Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins

Francesco Gaeta, Rocco Luigi Valluzzi, Cristiana Alonzi, Michela Maggioletti, Cristiano Caruso, Antonino Romano

Risultato della ricerca: Contributo in rivistaArticolo in rivista

54 Citazioni (Scopus)


BACKGROUND: Studies performed on samples larger than 100 subjects with a documented IgE-mediated hypersensitivity to penicillins have demonstrated a cross-reactivity rate of approximately 1% between penicillins and both imipenem and meropenem, whereas a single study found a cross-reactivity rate of 6.2% with aztreonam in 16 such subjects. OBJECTIVE: To assess the cross-reactivity and tolerability of aztreonam and 3 carbapenems (imipenem-cilastatin, meropenem, and ertapenem) in patients with documented IgE-mediated hypersensitivity to penicillins. METHODS: A total of 212 consecutive subjects with immediate reactions to penicillins and positive results on skin tests to at least 1 penicillin reagent underwent skin tests with aztreonam and carbapenems; subjects with negative results were challenged with escalating doses of aztreonam and carbapenems. RESULTS: All subjects displayed negative skin test results to both aztreonam and carbapenems; 211 accepted challenges and tolerated them. Challenges were not followed by full therapeutic courses. CONCLUSIONS: These data indicate the tolerability of both aztreonam and carbapenems in penicillin-allergic subjects. In those who especially require these alternative β-lactams, however, we recommend pretreatment skin tests, both because rare cases of cross-reactivity have been reported and because negative results indicate tolerability.
Lingua originaleEnglish
pagine (da-a)972-976
Numero di pagine5
RivistaJournal of Allergy and Clinical Immunology
Stato di pubblicazionePubblicato - 2015


  • Drug allergy


Entra nei temi di ricerca di 'Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins'. Insieme formano una fingerprint unica.

Cita questo